Bryan Vaughn is Executive Vice President & President, Diagnostics at Labcorp, where he oversees the company’s operating divisions and commercial growth strategy.
Bryan joined Labcorp in 2009, and since that time, has held multiple leadership roles. Most recently, he served as Senior Vice President, Health Systems & Mid-America Division, leading diagnostic operations across 19 states and managing enterprise partnerships with health systems and national accounts. He has led Labcorp’s health system growth strategy since 2017.
Previously, he served as Vice President of Finance for Labcorp’s Atlantic Division, and earlier, Director of Women’s Health Segment Marketing and Director of Strategic Planning and Corporate Development, where he helped shape business strategy, drive product development and expand Labcorp’s market presence.
Before joining Labcorp, Bryan worked in healthcare investment banking at Raymond James, a leading financial services firm, and in health advocacy at Cigna, a global health services company.
Bryan holds a Bachelor of Arts in economics from Vanderbilt University and a Master of Business Administration with a concentration in health sector management from Duke University’s Fuqua School of Business.
What is Bryan T. Vaughn's net worth?
The estimated net worth of Bryan T. Vaughn is at least $1.87 million as of July 2nd, 2026. Mr. Vaughn owns 6,746 shares of Labcorp stock worth more than $1,871,064 as of July 9th. This net worth approximation does not reflect any other assets that Mr. Vaughn may own. Learn More about Bryan T. Vaughn's net worth.
How do I contact Bryan T. Vaughn?
Has Bryan T. Vaughn been buying or selling shares of Labcorp?
During the past quarter, Bryan T. Vaughn has sold $66,968.46 of Labcorp stock. Most recently, Bryan T. Vaughn sold 234 shares of the business's stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $286.19, for a transaction totalling $66,968.46. Following the completion of the sale, the executive vice president now directly owns 6,746 shares of the company's stock, valued at $1,930,637.74. Learn More on Bryan T. Vaughn's trading history.
Who are Labcorp's active insiders?
Labcorp's insider roster includes Kerrii Anderson (Director), Jean-Luc Belingard (Director), Lance Berberian (EVP), Brian Caveney (EVP), Jonathan DiVincenzo (EVP and President, Central Laboratories and International), Glenn Eisenberg (CFO), Dwight Gilliland (Director), Paul Kirchgraber (CEO), Kathryn Kyle (Executive Vice President, Chief Legal Officer and Corporate Secretary), Jonathan Meltzer (EVP), Peter Neupert (Director), Richelle Parham (Director), Adam Schechter (Chairman, President, and CEO), Mark Schroeder (EVP), Amy Summy (CMO), Sandra van der Vaart (EVP), Bryan Vaughn (Executive Vice President and President, Diagnostics), Peter Wilkinson (CAO), and R. Williams (Director). Learn More on Labcorp's active insiders.
Are insiders buying or selling shares of Labcorp?
During the last year, insiders at the medical research company sold shares 15 times. They sold a total of 50,904 shares worth more than $13,710,584.45. The most recent insider tranaction occured on July, 2nd when EVP Kathryn W Kyle sold 92 shares worth more than $26,329.48. Insiders at Labcorp own 0.8% of the company.
Learn More about insider trades at Labcorp. Information on this page was last updated on 7/2/2026.
